Koethe JR, Lake JE, Kantor A, Smeaton L, Erlandson K, Moran L, Belaunzaran-Zamudio P, Landay A, Campo RE, Debroy P, Bennet JA, O'Halloran J, Han WM, Alli O, Leonard M, Gulick RM. A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391). Clin Infect Dis. 2026 Jul 23; 83(1):e81-e89.

Ridolfi F, Amorim G, Haas DW, Arriaga M, Staats C, Cordeiro-Santos M, Kritski AL, Figueiredo MC, Andrade BB, Sterling TR, Rolla VC, Benjamin A, Sant'Anna FM, Oliveira JG, Marin J, Rezende A, Carvalho AC, Rocha M, Nogueira B, Brito A, Spener R, Turner M. Determinants of HIV-1 virologic suppression in HIV-associated tuberculosis in Brazil. Mem Inst Oswaldo Cruz. 2026; 121:e250090.

Torres TS, Silva MST, Hoagland B, Marins LMS, Coutinho C, Jalil EM, Leite P, Cunha M, Moreira R, Leite IC, Konda K, Guanira J, Benedetti M, Pimenta C, Vega-Ramirez H, Cardoso SW, Caceres CF, Anderson PL, Grinsztejn B, Veloso VG. Using Tenofovir Diphosphate Levels to Evaluate Factors Associated With PrEP Non-Adherence and Performance of Indirect Adherence Measures in Latin America: A Prospective, Single-Arm, Open-Label, Multicentre Implementation Study (ImPrEP). J Int AIDS Soc. 2026 Jul; 29 Suppl 3:e70154.

Oyaro P, Basha GW, Thomas KK, Brown E, Hassan SA, Imran R, Karauki E, Yongo N, Maheria P, Patel RC, Abuogi LL. Predictors of Sustained Viral Suppression among Children Living with HIV in Kenya: Secondary Analysis of Data from a Randomized Control Study. J Pediatric Infect Dis Soc. 2026 Jun 12; 15(6).

Abuogi LL, Carlucci JG, Edmonds A, Regula L, Sugandhi N, Yin DE, Edwards JK. A Systematic Review of the Use of Antiretroviral Drugs to Prevent HIV in Neonates and Infants. J Pediatric Infect Dis Soc. 2026 Jun 12; 15(7).

Valentin OR, Henderson C, Coffin LS, Paredes-Gotamco J, Olem D, Farrales W, Neilands TB, Dilworth SE, Doblecki-Lewis S, Page K, Moskowitz JT, Anderson PL, Johnson MO, Carrico AW. Positive psychological intervention to reduce HIV acquisition risk with men who use stimulants: protocol for a randomised controlled trial. BMJ Open. 2026 May 11; 16(5):e120232.

Khaitan A, Lindsey JC, Capparelli EV, Tierney C, Coletti A, Perlowski C, Yin DE, Smith MEB, Spiegel HML, Majji S, Moye J, Gama L, Koup RA, Lin BC, McDermott AB, Purdue L, Krotje C, Harding PA, Cotton MF, Costello D, Petropoulos CJ, Reeves JD, Mallewa M, Chihana R, Kamthunzi P, Mbengeranwa TG, Masheto G, Santos Cruz ML, Pilotto JH, Ponatshego PL, Persaud D, McFarland EJ. VRC01 with antiretroviral initiation in infants is well tolerated, and higher concentrations associate with greater HIV-1 DNA declines. Sci Transl Med. 2026 May 06; 18(848):eadr4509.

Colasanti JA, Aldredge A, Niles-Carnes LV, Ochieng E, Pareek P, Robinson V, Anderson E, Castaneda M, Spralling H, Smith BL, Sumitani J, Paul Leue E, Moran CA, Lora M, Armstrong WS, Collins LF. Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South. Clin Infect Dis. 2026 Apr 30; 82(4):564-574.

Beck IA, Boyce CL, Bishop MD, Oldroyd AR, du Toit L, Saimen A, Ramarope KM, Hitchcock S, du Plessis NM, Mbogo L, Chohan BH, Maheria P, Oyaro P, Knowles K, Zhang Z, Brummel SS, Drain PK, Smith RA, Gottlieb GS, Abuogi L, Patel RC, Farquhar C, Wiznia A, Ruel TD, Rossouw TM, Hawes SE, Frenkel LM. HIV Resistance to Dolutegravir Varies With Coadministered Agents. Clin Infect Dis. 2026 Apr 30; 82(4):592-596.

Mann SC, Lykins D, Coyle RP, Witt MD, Kim EY, Macatangay B, Brown TT, Dionne JA, Alcaide M, Lahiri CD, Ramirez C, Dumond JB, D'Souza G, Cohen MH, Wilson TE, Kassaye S, Tien PC, Adedimeji AA, Ellison L, Brooks KM, Bushman LR, Anderson PL, MaWhinney S. In the Mismatch: Viral Suppression Despite Low Tenofovir-Diphosphate in Dried Blood Spots in the Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort. Clin Infect Dis. 2026 Apr 30; 82(4):575-582.